arrow_back Trending Legislation
Share share

Increasing Access to Biosimilar Drugs in Medicare Program

This act aims to increase the availability of more affordable biosimilar drugs for individuals covered by Medicare. It establishes a pilot program to encourage healthcare providers to use these drugs more frequently, potentially lowering treatment costs for patients and the healthcare system.
Key points
Pilot Program: A 3-year program will be established to evaluate the benefits of additional payments to providers for using biosimilar drugs.
No Increased Patient Costs: Additional payments to providers will not increase Medicare beneficiaries' out-of-pocket costs.
Voluntary Participation: Provider participation in the program is voluntary, and they can withdraw at any time.
Reports to Congress: The Secretary of Health and Human Services will regularly report to Congress on the program's results, potentially leading to its expansion.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Increasing Access to Biosimilars Act of 2021
Print number: HR 2869
Sponsor: Rep. Cárdenas, Tony [D-CA-29]
Process start date: 2021-04-28
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Increasing Access to Biosimilar Drugs in Medicare Program

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 2869.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • Pilot Program: A 3-year program will be established to evaluate the benefits of additional payments to providers for using biosimilar drugs.
  • No Increased Patient Costs: Additional payments to providers will not increase Medicare beneficiaries' out-of-pocket costs.
  • Voluntary Participation: Provider participation in the program is voluntary, and they can withdraw at any time.
  • Reports to Congress: The Secretary of Health and Human Services will regularly report to Congress on the program's results, potentially leading to its expansion.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Cárdenas, Tony [D-CA-29].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

Analysis and Potential Impact of HR 2869

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health